Skip to Main Content
Back to News

Lobbying Update: $10,000 of AMICUS THERAPEUTICS INC. lobbying was just disclosed

None

$10,000 of AMICUS THERAPEUTICS INC. lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"newborn screening, prescription drug affordability"

You can find more data on corporate lobbying on Quiver Quantitative.

FOLD Hedge Fund Activity

We have seen 152 institutional investors add shares of FOLD stock to their portfolio, and 125 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

FOLD Analyst Ratings

Wall Street analysts have issued reports on $FOLD in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • Needham issued a "Buy" rating on 09/18/2025
  • Morgan Stanley issued a "Overweight" rating on 07/17/2025
  • UBS issued a "Buy" rating on 05/02/2025

To track analyst ratings and price targets for FOLD, check out Quiver Quantitative's $FOLD forecast page.

FOLD Price Targets

Multiple analysts have issued price targets for $FOLD recently. We have seen 4 analysts offer price targets for $FOLD in the last 6 months, with a median target of $18.0.

Here are some recent targets:

  • Gil Blum from Needham set a target price of $14.0 on 09/18/2025
  • Jeffrey Hung from Morgan Stanley set a target price of $108.0 on 07/17/2025
  • Karl Chalabala from UBS set a target price of $22.0 on 05/02/2025
  • Salveen Richter from Goldman Sachs set a target price of $9.0 on 05/02/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles